• 18
  • Image

GA-map™ Dysbiosis Test in new breakthrough for IBS patients

(Vienna, October 18, 2016) A low-FODMAP diet is now an established treatment for people with irritable bowel syndrome (IBS), but the diet is controversial and challenging to follow, and not all IBS sufferers have a positive response to the intervention. Today, scientists at UEG Week have announced that bacterial profiles in the faeces differ between people who do and do not respond to a low-FODMAP diet, allowing doctors to predict who might benefit most from using the diet. Bacterial composition was evaluated by GA-map™ Dysbiosis Test, from Genetic Analysis AS.

A press release from the ongoing UEG Week conference in Vienna, informs about a new breakthrough for IBS patients. Presenting their findings for the first time at the opening session of UEG Week 2016, Dr Sean Bennet from the University of Gothenburg in Sweden, told delegates that, in the right people, a low-FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) diet can be highly effective, but identifying those individuals is currently impossible. “A low-FODMAP diet has been shown in a recent clinical trial to significantly reduce the symptoms of IBS in around half of the people who tried it,” he said. “Unfortunately, this is a very demanding diet that requires the exclusion of entire food groups, so we have been looking at ways to predict who will gain the greatest benefit from trying it.”
In the current study, the microbiota status was evaluated in patient samples by GA-map™ Dysbiosis Test. “Patients who did not respond to the low-FODMAP diet were found to have more abnormalities in their gut bacterial profiles before they started the diet than those who responded to the diet,” said Dr Bennet. “This raises the possibility that faecal bacterial profiling could be undertaken before dietary interventions are considered. Being able to predict if a patient is unlikely to respond to a low-FODMAP diet means that other therapies could be discussed earlier, and these patients could be spared a demanding diet that might have no effect, or even worsen, their symptoms.”

This study was selected as one of the top five abstracts submitted to UEG Week 2016

UEGW press release
About Dr Sean Bennet

Dr Bennet is from the Department of Internal Medicine at the University of Gothenburg, Sweden. His study on gut microbial profiles and low-FODMAP diets has been selected as one of the top five abstracts submitted to UEG Week Vienna 2016: https://www.ueg.eu/awards-grants/ueg-week-awards/top-abstract-prize/

About UEG Week

UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.

About Genetic Analysis

Genetic Analysis has developed and launched the first gene-based routine test for the mapping and diagnosis of diseases related to dysbiosis and imbalances in the bacteria in the digestive system. The company markets the GA-map™ technology to three market segments: commercial routine testing, pharma companies and the research market. Genetic Analysis was established in 2008 and is based on research done by Professor Knut Rudi at Norwegian University of Life Sciences, NMBU and Nofima Mat in Ås.

Comments are closed.